Dr Spira on the Ongoing Investigation of MYTX-011 in NSCLC
Alexander I. Spira, MD, PhD, FACP, discusses a phase 1 study of the antibody-drug conjugate MYTX-011 in patients with non–small cell lung cancer.
Source: onclive.com
Page 6 - Phasei Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phasei Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phasei Program Today - Breaking & Trending Today
Evaluation of Novel Agents and Combinations Aims to Improve Outcomes in Frontline RCC
Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.
Source: onclive.com
Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC
Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.
Source: onclive.com
Investigation of Ubamatamab With or Without Cemiplimab Continues in Recurrent Ovarian Cancer
The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.
Source: onclive.com
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech's SNK01 NK Cells
Stable disease was observed in three out of seven heavily pretreated patientsNo dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 -- Affimed N.V. ...
Source: marketscreener.com